No headlines found.
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire (Wed, 4-Sep 4:05 PM ET)
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Globe Newswire (Wed, 14-Aug 6:00 AM ET)
Globe Newswire (Tue, 13-Aug 8:00 AM ET)
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
Globe Newswire (Thu, 8-Aug 4:05 PM ET)
Apollomics - Warrant trades on the stock market under the symbol APLMW.
As of November 8, 2024, APLMW stock price was flat at $0.01 with 85,547 million shares trading.
APLMW has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
APLMW has underperformed the market in the last year with a return of -45.4%, while the SPY ETF gained +38.5%. In the last 3 month period, APLMW fell short of the market, returning +1.8%, while SPY returned +15.7%. However, in the most recent 2 weeks APLMW has outperformed the stock market by returning +12.0%, while SPY returned +3.3%.
APLMW support price is $.01 and resistance is $.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLMW shares will trade within this expected range on the day.